Maxingshigan Tablets Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a multi-marker botanical active pharmaceutical intermediate intended for further manufacture rather than direct administration to animals. The material is prepared from a fixed-ratio botanical formula containing Ephedra Herba, Gypsum Fibrosum, Armeniacae Semen Amarum, and Glycyrrhizae Radix et Rhizoma. Identity and assay markers therefore include ephedrine hydrochloride, pseudoephedrine hydrochloride, amygdalin, glycyrrhizic acid, and calcium sulfate dihydrate. No single harmonized monograph exists under the exact product name; the receiving jurisdiction establishes acceptance criteria through the finished-product applicant’s registration file. The model designation is therefore a grade matrix rather than a single model number. That matrix separates spray-dried extract for tablets, purified clarified extract for injections, sieved powder for capsules, milled material for granules, flowable dry-mix powder for premix use, and dissolved or suspended extract for oral solutions.

Specifications are batch-specific and dosage-form-specific. A tablet-grade API may be released with particle-size distribution measured by laser diffraction according to ISO 13320, while an injection-grade API is released with additional bacterial endotoxin and bioburden limits. Marker content alone is not sufficient for release. The supplier certificate of analysis typically includes total ephedrine alkaloids, pseudoephedrine content, amygdalin, glycyrrhizic acid, loss on drying, residue on ignition, heavy metals, pesticide residues, residual solvents, total plate count, yeast and mold, and specified organisms. Quantification is performed by HPLC or UHPLC with photodiode array detection because no single ultraviolet-visible absorbance method separates all marker classes. The lower marker concentration of Ephedra Herba in ChP 2020 is 0.8% combined ephedrine hydrochloride and pseudoephedrine hydrochloride; the final extract ratio may concentrate these alkaloids but must not concentrate heavy metals or pesticide residues beyond the registration limit.

Specification and Batch Release Matrix for Multi-Form Veterinary APIs

The use of this API is confined to further pharmaceutical processing. It is blended into tablet formulations by wet granulation or direct compression, filled into hard capsules, dispersed in dry premixes for feed, converted into granules by fluid-bed processing, or dissolved or suspended in solutions. Each route applies different pressure, heat, and shear histories. The tablet route requires compression at forces that do not induce lamination of the botanical extract. The injectable route requires a sterilizing filtration or terminal sterilization decision that tablet-grade material cannot satisfy. The premix route requires homogeneity testing at low inclusion. In all cases, the API is not a finished product and cannot be used as a replacement for a registered veterinary medicinal product. Each finished product must justify target species, dose, route, and withdrawal period through the applicable veterinary drug authority.

Why Does Injection-Grade Processing Reject Tablet-Grade Powder Even If Marker Assay Matches?

Matching marker content does not indicate interchangeability across dosage forms. Tablet-grade powder routinely contains calcium sulfate, insoluble cell wall fragments, and small quantities of flow-enhancing materials that are not acceptable in a clear injectable solution. A sterile filtration train with a 0.45 µm prefilter and a 0.22 µm sterilizing membrane will foul if calcium sulfate concentration exceeds the solution saturation limit or if the extract has a high colloid burden. Injection-grade API is therefore produced under a separate purification strategy, commonly involving centrifugation, ultrafiltration, or membrane clarification. The production area must meet EU GMP Annex 1 and ISO 14644-1. Endotoxin control is dose-based; passage through a 0.22 µm filter removes bacteria but not endotoxin. The maximum allowable endotoxin for an injectable is calculated from the intended dose volume and the target species sensitivity, and it cannot be copied from a tablet-grade certificate of analysis. The same concern applies to injection-grade stability: if the API is lyophilized, the residual moisture after freeze-drying must be low enough to prevent glass transition collapse and marker degradation, but the specific moisture target is product-dependent. Published data for this exact botanical injection-grade API is limited; each manufacturer must generate filter-flux, endotoxin-reduction, and stability data before release of a sterile finished product.

For oral powder and premix manufacturing, the dominant production bottleneck is segregation rather than solubility. A spray-dried multicomponent extract with a tapped bulk density below 0.40 g/cm³ can stratify in ribbon blenders, especially if the mixer is filled beyond its validated working volume. An angle of repose greater than 40° indicates that glidant addition is necessary before filling or dosing. Content uniformity testing on finished premix is mandatory when the API inclusion rate is below 1.0% by weight. Sampling from at least 10 locations per batch and HPLC marker assay provide evidence that the dry-mix form is suitable for field dilution. Increasing mixing time beyond the qualified range does not improve homogeneity; it may raise the powder-bed temperature and change the recovery of heat-sensitive markers. On production lines with high ambient humidity, the extract surface adsorbs moisture, and the powder transitions from free-flowing to cohesive at a threshold that must be established for the specific extract ratio. Pre-drying at low temperature is required when relative humidity exceeds 60%, and opened containers should be resealed under dry conditions to avoid batch-to-batch flow variation.

When a Single Extract Is Dry-Mixed, Wet-Granulated, or Sterile-Filtered Across Species

Dry-mixing of the unprocessed extract is not equivalent to wet granulation. In wet granulation, the polysaccharides present in licorice root function as a natural binder and can reduce the amount of external binder needed. However, the same polysaccharides extend disintegration time in tablet forms. A disintegration limit in the finished product must be set according to USP <701> or the applicable ChP method. The calcium sulfate component acts as a filler and hardening agent in tablets, which is advantageous for hardness but creates a precipitation risk in solutions. If a clear oral solution is required, calcium sulfate must be removed or reduced, or the formulation must be designated as a suspension. For granules, fluid-bed spray rate and inlet air temperature must be validated because the extract is heat-sensitive; a high intake temperature can reduce marker recovery, but the threshold must be determined by forced degradation. In capsule filling, the API powder is combined with diluents and glidants; flow characterization follows USP <1216> and the filled capsule is tested for weight variation or uniformity of dosage units according to USP <905>.

Rotary tablet presses with a precompression stage are used to avoid lamination. The botanical extract exhibits elastic recovery after compaction; if precompression is missing, crown cracking appears on the tablet surface. Compression force and turret speed are set to maintain tablet hardness while ensuring disintegration. The tablet-grade API may contain residual moisture; if the moisture content is too low, the tablets undergo capping; if too high, sticking occurs. Batch-to-batch variation in loss on drying should be controlled within a range established by the manufacturer, and incoming API should be re-tested after storage above 60% relative humidity.

Contrast With Single-Entity Synthetic Respiratory APIs and Single-Herb Extracts

The product differs from synthetic respiratory agents such as ketoprofen, carprofen, bromhexine hydrochloride, or amoxicillin in that it has no single pharmacopeial potency unit. A synthetic API is one molecular entity with a single melting point, a single assay wavelength, and a defined impurity profile. This API has a minimum of four marker classes and requires a chromatographic fingerprint. Consequently, dissolution testing cannot be transferred from a single-entity product; it must track the marker or markers that are relevant to the intended formulation. If ephedrine is selected as the dissolution marker, its water-soluble salt form may mask formulation differences; if amygdalin is selected, temperature and pH stability of the sample must be controlled. Published data for this exact finished combination in veterinary species is limited, so therapeutic equivalence cannot be assumed from marker content alone.

Compared with a single-herb ephedra extract or a single-herb licorice extract, this product contains calcium sulfate from gypsum. That mineral component changes the density and tableting behavior of the dry extract and is a major reason that tablet-grade powder cannot be directly substituted into an injectable solution. The fixed formula ratio also creates an analytical constraint: if one raw herb lot has a low marker content, it cannot be corrected by simply adding isolated marker compounds. The botanical ratio must be maintained, and the extraction process must be adjusted against the formula. The product is therefore supplied to manufacturers as a standardized intermediate, not as a synthetic chemical whose impurity profile can be definitively indexed.

Regulatory handling differs as well. Ephedra-derived alkaloids are subject to precursor or controlled-substance controls in certain jurisdictions. Import, export, and inventory records may require a veterinary drug import permit, a good manufacturing practice certificate, and an end-use declaration. Unopened material should be stored in a cool, dry, controlled-access area. If storage is not under controlled access, supply-chain compliance rather than pharmacopeial chemistry may become the limiting specification.